Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT00706862 is registered in ClinicalTrials.gov with Agennix as lead sponsor.

NCT NCT00706862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00706862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Lead sponsor
Agennix
Phase
Phase 3
Overall status
Unknown status
Start date
February 28, 2009
Completion date
March 31, 2016
Enrollment
1,100 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer